Vincent Jacques

Dr. Vincent Jacques is an established drug discovery and early development team leader, innovative problem solver, and execution-focused scientific leader with over 15 years of industry experience in both publicly-traded and private biopharmaceutical companies. He has an extensive background in ADME/PK, formulation, in vitro biology, in vivo animal models, and medicinal, bioconjugate, inorganic, and radio chemistry. At the University of Liege, Jacques earned his B.S. in Chemistry with highest honors in 1988 and his PhD in Chemistry summa cum laude in 1994 with the thesis, “Macrocyclic lanthanide and actinide complexes: synthesis and properties.” He has extensive experience in therapeutic and diagnostic contrast agent research, including small molecules, peptide derivatives, and particles in several disease areas, including CNS (such as Alzheimer’s disease, obesity, cognition, neurodegenerative diseases), pain (neuropathic, visceral), inflammation, metabolic disease (NASH), orphan diseases, and gastrointestinal (IBS, IBD, chronic constipation) indications. During his time at EPIX Pharmaceuticals (2001-2009), Dr. Jacques contributed to the discovery of gadolinium complexes for MRI and managed all in-house in vivo and in vitro drug metabolism and pharmacokinetics (DMPK) studies. Following his time at EPIX, Vincent acted as Senior Director of Preclinical Development at RelpiGen Corporation in Waltham, MA, where he led RepliGen’s effort in collaboration with 4 academic laboratories on Huntington’s disease (UO1 grant). Currently, Vincent serves as SVP of Research & Early Development at DeuteRx, LLC, as a founding member of the leadership team. At DeuteRx, he coordinates all research activities including collaborations with strategic service providers and partners. He is an inventor on several issued patents and/or patent applications and author of over 40 publications, including abstracts and presentations at scientific meetings.